Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/8/2024 | $13.00 → $11.00 | Outperform | Oppenheimer |
5/31/2024 | $11.00 | Overweight | Piper Sandler |
1/5/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
1/5/2024 | Buy → Neutral | Guggenheim | |
12/8/2023 | $7.00 | Buy | Citigroup |
12/8/2023 | Buy | Citigroup | |
6/26/2023 | $28.00 | Outperform | Oppenheimer |
3/21/2023 | $6.00 | Mkt Perform | Bernstein |
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in November. Stifel 2024 Healthcare ConferenceMonday, November 18, 20245:35AM PT/8:35AM ET Jefferies London Healthcare ConferenceWednesday, November 20, 202410:00AM GMT/ 5:00AM ET Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be availa
Conference Call and Webcast Scheduled for November 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report third quarter 2024 financial results and provide a business update on November 7, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Company's website at ww
RMAT Designation Follows Positive Proof-of-Concept Data from the ALLO-316 TRAVERSE Trial in Adult Patients with Advanced or Metastatic CD70 Positive Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting TherapyALLO-316 Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion of an "Off-the-Shelf" CAR T ProductCompany to Present Updated Phase 1 Data from the TRAVERSE Trial at the Society for Immunotherapy of Cancer (SITC) Annual MeetingALLO-316 was Previously Granted Fast Track Designation (FTD) in March 2022 by the U.S. Food and Drug Administra
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer. Mr. Parker will oversee the Company's financial operations and business strategy and will serve as a member of the Leadership Team. "Geoff's extensive experience in biotechnology across all aspects of finance and business development strategy will be of tremendous value to Allogene as we advance our critical pipeline assets and explore new opportunities," said David Chang, M.D., Ph.D.
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that Earl Douglas has been appointed as General Counsel. Mr. Douglas will oversee all aspects of the Company's legal function and serve as a member of the Leadership Team. "We are excited to welcome Earl who brings a tenure of experience guiding publicly-traded biotech companies on complex legal issues, corporate strategy and transactions," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "I also want to th
144 - Allogene Therapeutics, Inc. (0001737287) (Subject)
144 - Allogene Therapeutics, Inc. (0001737287) (Subject)
10-Q - Allogene Therapeutics, Inc. (0001737287) (Filer)
Conference Call and Webcast Scheduled for November 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report third quarter 2024 financial results and provide a business update on November 7, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Company's website at ww
Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024Patient Screening for Minimal Residual Disease (MRD) and Enrollment Proceeding as Planned with Ten Community and Academic Sites Opened to Date Across the USEnrollment Completion Expected in 1H 2026 and Potential BLA Submission in 2027 ALLO-329 in Autoimmune Disease (AID) Investigational New Drug (IND) Application for Next-Generation CD19/CD70 Dual CAR with Dagger® Technology Designed for AID on Track for Q1 2025 with Proof-of-Concept Data Expected by YE 2025 ALLO-316 in Renal Cell Carcinoma (RCC) Phase 1 TRAVERSE Data Update Including Details on the Diag
Conference Call and Webcast Scheduled for August 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report second quarter 2024 financial results and provide a business update on August 7, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Company's website at www.a
A revolutionary cell-based gene therapy is showing promise for treating autoimmune diseases. Professor Georg Schett, a rheumatologist at University Hospital Erlangen in eastern Germany, used chimeric antigen receptor (CAR-T) cell therapy, typically used for blood cancers, for autoimmune conditions like lupus, when the immune system attacks healthy cells and tissues by mistake. This attack causes inflammation. The Financial Times writes that the early success of CAT-T therapy has reignited discussions about its potential beyond blood cancers, though challenges remain. Professor Georg Schett noted that this approach could revolutionize autoimmune disease treatment, providing a one-tim
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer InstituteALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (1L) Treatment at Community Cancer Centers, Where 80% of Patients Receive CareALPHA3 Expected to Complete Enrollment in 1H 2026; Potential BLA Submission in 2027
ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure Rates First Prospective Trial to Incorporate the Foresight Diagnostics's Investigational CLARITY™ Test to Identify Patients with LBCL Who Have Minimal Residual Disease (MRD) and are Likely to Relapse Following Standard 1L TreatmentUnique Profile of Investigational AlloCAR T™ Products May Expand Access to CAR T within Community Cancer Centers where Most 1L Patients are ManagedALPHA3 Expected to Complete Enrollment in 1H 2026; BLA Submission Anticipated in 2027
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
Oppenheimer resumed coverage of Allogene with a rating of Outperform and set a new price target of $11.00 from $13.00 previously
Piper Sandler initiated coverage of Allogene with a rating of Overweight and set a new price target of $11.00
JMP Securities downgraded Allogene from Mkt Outperform to Mkt Perform
SC 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)
SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)
SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)